Most businesses earn when a customer pays at the point of sale. Community pharmacy works differently. The dominant income stream does not come from the shop till at all: it comes from the NHS, paid weeks after the dispensing took place, at prices set not by the pharmacy but by central government. Understanding this structure is the starting point for anyone who owns, buys, or is thinking about acquiring a pharmacy.
Note: The NHS contract arrangements described here apply in England. Scotland, Wales and Northern Ireland operate under separate contractual frameworks; content covering those jurisdictions will be published as a post-launch extension.
How pharmacies make money, in one paragraph
A community pharmacy in England earns mainly through the NHS Community Pharmacy Contractual Framework (CPCF): reimbursement for the drugs it dispenses at Drug Tariff prices, plus remuneration in the form of dispensing fees and service payments. A smaller layer of over-the-counter retail and private-service income sits alongside. The income is contract-driven, not till-driven: the NHS contract, and the volume of prescriptions it generates, is the business. The shop is the delivery vehicle.
The NHS contract is the engine
Every NHS prescription dispensed by a community pharmacy in England generates a claim under the CPCF. That claim has two components: reimbursement and remuneration.
Reimbursement covers the cost of the drugs themselves. NHSBSA prices each item against the Drug Tariff and pays back what it calculates the pharmacy is owed. The pharmacy does not set these prices.
Remuneration covers the fees for providing the dispensing service: dispensing fees, practice-payment elements, and service payments such as Pharmacy First. These are also centrally determined and published.
Both components are claimed through the FP34 monthly submission to NHSBSA. The NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 govern who can hold an NHS contract and on what terms. Entry is regulated: you cannot simply open a pharmacy and join the NHS payment system without meeting the regulatory criteria. This is why the NHS contract, not the premises, is the dominant asset when a pharmacy changes hands.
Reimbursement versus remuneration: the two halves of NHS income
The distinction matters for management accounts and for valuation.
| Income component | What it covers | Who sets it | Accounting note |
|---|---|---|---|
| Drug reimbursement | Cost of drugs dispensed, priced against the Drug Tariff and Category M list prices | NHSBSA / Department of Health (centrally) | Zero-rated for VAT; gross margin is not controlled by the pharmacy and is subject to retrospective Category M adjustments |
| Dispensing fees | Per-item and per-prescription fees for the dispensing service | NHS England / CPCF negotiation | Part of remuneration; flows through FP34 alongside reimbursement |
| Service payments | Pharmacy First and other commissioned services | NHS England | Separately accounted; own fee structure and activity thresholds |
| OTC and private retail | Medicines and products sold without a prescription; private consultations and services | The pharmacy (market-priced) | Standard-rated for VAT (generally); different margin economics from dispensing |
The critical point on reimbursement is that Drug Tariff prices and Category M rates are set centrally and adjusted retrospectively. A pharmacy cannot improve its reimbursement margin by negotiating better prices or by selling more persuasively. The margin is what the system sets it to be. This is why Category M clawbacks and Drug Tariff changes are a recurring management-accounts event, not a one-off. It is also why benchmarking your actual margin against sector norms is a more useful exercise than trying to manage the reimbursement rate itself. See pharmacy margin benchmarking for how that analysis works in practice.
Service income: the growing line
Pharmacy First is the most visible current example of NHS-commissioned service income: a separately funded programme through which community pharmacies provide clinical consultations for a defined set of conditions, reducing pressure on GP surgeries. It carries its own fee structure and activity thresholds, and it is accounted for separately from core dispensing reimbursement.
For management-accounts and valuation purposes, service income is worth tracking as a distinct line. It reflects active delivery of commissioned services rather than volume of prescriptions processed, and it is the area where policy change is most likely to shift the income mix over the coming years.
No specific fee figures are stated here because the fee schedules are updated by NHS England and any figure quoted risks becoming stale. Current published rates can be found on the NHS England Pharmacy First pages. See also how Pharmacy First income is accounted for for the practical bookkeeping treatment.
The retail and OTC layer, and why it is different
Most community pharmacies sell over-the-counter medicines and related products alongside their NHS dispensing. This retail income is market-priced and the pharmacy can influence its margin directly, unlike reimbursement. However, the economics carry a structural difference that does not apply to a normal shop.
NHS-dispensed prescription drugs are zero-rated for VAT; most OTC retail sales are standard-rated at 20%. A pharmacy is structurally a VAT-mixed business. The zero-rated dispensing volume means that input VAT on costs related to that activity is reclaimable, which changes the effective cost base compared with a pure retailer. Getting the VAT split right, using an appropriate retail scheme to apportion mixed sales, matters materially at pharmacy scale.
The OTC retail layer also does not replace the NHS contract as the core earnings driver. For most community pharmacies, the dispensing volume and the NHS fees attached to it are what determine the business's value. See how VAT works in a pharmacy for the detail on the zero-rated and standard-rated mix.
Why the till does not tell you the profit
Two features of NHS income mean that cash in the bank and income earned are always out of step in a community pharmacy.
First, the timing. Prescriptions dispensed in a given month are submitted to NHSBSA the following month via the FP34 process, and the balancing payment arrives roughly two months after the original dispensing. An advance on account is paid earlier in the cycle, but it does not close the gap. At any point in time, a pharmacy has months of NHS income in transit between dispensing and settlement. The FP34 payment cycle explains the mechanics in full, and the FP34 cash-flow estimator lets you model the lag against your own dispensing volume.
Second, the price. The amount NHSBSA settles is based on centrally set Drug Tariff prices and is subject to Category M retrospective adjustment. A pharmacy that has dispensed a large volume of Category M items may find that the payment received differs from what was estimated at the point of dispensing. Reconciling the settlement against the FP34 submission is a routine but load-bearing monthly task, not an optional check. See Drug Tariff changes explained and Category M clawbacks explained for the mechanics of each.
What this means if you own or are buying a pharmacy
Because income is contract-driven rather than retail-driven, the core financial discipline in a community pharmacy is different from most owner-managed businesses. Margin is not set by the owner, so the levers are volume, overhead control, service income development, and working-capital management around the FP34 lag. Profit improvement comes from operational efficiency and service income growth, not from repricing the dispensing line.
For buyers, the implication is that what you are acquiring is principally the NHS contract, the volume of prescriptions it attracts, and the history of margin that goes with it. Goodwill, driven by contract volume and item count, is typically the dominant component of the purchase price. The Pharmacy Openings and Closures Index tracks the structural changes in supply across England and provides context for how contract availability and consolidation dynamics are moving at a market level. If you are evaluating a specific acquisition, the pharmacy buyer's checklist, the finance mechanics for first-time buyers, and the worked investment figures all build on this revenue-model foundation.
For owners, the monthly accounting workflow sits on top of this same structure: FP34 reconciliation, Category M variance tracking, service-income reporting, and payroll cost management are the recurring tasks that determine whether the business's profit matches its dispensing activity. If you want to understand how your pharmacy's margin compares with the sector, pharmacy benchmarking is the service that surfaces that data.
The buying a pharmacy hub covers the acquisition journey end to end, and pharmacy owners covers the ongoing finance and tax picture.